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Purpose: The purpose of the study is to evaluate the effectiveness of risk minimiza-
tion measures—labeling changes and communication to health care professionals—
recommended by the European Medicines Agency for use of cilostazol for the treat-
ment of intermittent claudication in Europe.
Methods: Observational study of cilostazol in The Health Improvement Network
(United Kingdom), EpiChron Cohort (Spain), SIDIAP (Spain), Swedish National Data-
bases, and GePaRD (Germany).
Among new users of cilostazol, we compared the prevalence of conditions targeted
by the risk minimization measures in the periods before (2002‐2012) and after
(2014) implementation. Conditions evaluated were prevalence of smoking, cardiovas-
cular conditions, concurrent use of ≥2 antiplatelet agents, concurrent use of potent
CYP3A4/CYP2C19 inhibitors and high‐dose cilostazol, early monitoring of all users,
and continuous monitoring of users at high cardiovascular risk.
Results: We included 22 593 and 1821 new users of cilostazol before and after
implementation of risk minimization measures, respectively. After implementation,
the frequency of several conditions related to the labeling changes improved in all
the study populations: prevalence of use decreased between 13% (EpiChron) and
57% (SIDIAP), frequency of cardiovascular contraindications decreased between 8%
(GePaRD) and 84% (EpiChron), and concurrent use of high‐dose cilostazol and potent
CYP3A4/CYP2C19 inhibitors decreased between 6% (Sweden) and 100% (EpiChron).
The frequency of other conditions improved in most study populations, except
smoking, which decreased only in EpiChron (48% reduction).
Conclusions: This study indicates that the risk minimization measures implemented by
theEMA for theuse of cilostazol havebeeneffective in all European countries studied, except
for smoking cessation before initiating cilostazol, which remains an area of improvement.- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
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• This study evaluated the effectiveness of risk
minimization measures among new users of cilostazol
in the United Kingdom, Spain, Sweden, and Germany.
• The observed decrease in the prevalence of cilostazol
use, cardiovascular contraindications, and concurrent
use of 2 or more antiplatelet drugs or interacting
medications indicates that the risk minimization
measures were effective in all the study populations.
• Stopping smoking before initiating cilostazol remains an
area of improvement, as prevalence of smoking after
risk minimization measures decreased in only 1 of 4
study populations where smoking was evaluated.1 | INTRODUCTION
Cilostazol is a platelet aggregation inhibitor approved in Europe in
2002 to improve walking distances in patients with intermittent clau-
dication. Cilostazol has been associated with spontaneous reports of
serious bleeding and cardiovascular effects including heart attacks,
angina, and arrhythmias. The European Medicines Agency (EMA) eval-
uated the benefits and risks of cilostazol in a referral and recom-
mended implementation of risk minimization measures to restrict the
use of cilostazol to patients that could benefit from treatment and in
which important risks are minimized.1 Risk minimization measures
included labeling changes (Table 1) and educational communications
directed to health care professionals through the Otsuka Europe
website and “Dear Doctor” letters implemented in 2013.
To evaluate the impact of these risk minimization measures, we
compared the prevalence of cilostazol use and of the conditions
targeted by these risk minimization measures before and after these
measures were implemented.2 | METHODS
2.1 | Data sources
The study was conducted in The Health Improvement Network
(THIN), UK2-4; the EpiChron cohort (EpiChron) from the Aragon Insti-
tute of Health Sciences (IACS), Aragon, Spain5,6; the Information Sys-
tem for Research in Primary Care (SIDIAP), Catalonia, Spain7; the
Swedish National Registers8,9; and the German
Pharmacoepidemiological Research Database (GePaRD).10 The main
features of the study databases are presented in Table S1, online
supporting information. The baseline characteristics of users of
cilostazol before implementation of risk minimization measures have
been published elsewhere.112.2 | Study population
New users of cilostazol were identified before and after implementa-
tion of risk minimization measures (Figure 1). The period before imple-
mentation was from the date cilostazol became available in each
country through September 14, 2012 in THIN; December 31, 2012
in EpiChron, SIDIAP, and Sweden; and December 31, 2011 in
GePaRD. Data for the year 2012 were not available in GePaRD at
the time of the baseline assessment.11 The period after implementa-
tion was the year 2014. New users were defined as patients who
received a first‐ever prescription of cilostazol during each study period
after having at least 6 months of continuous enrollment in the data-
base. The date of the first cilostazol prescription was defined as the
start date. Patients with a recorded prescription of cilostazol at any
time before the start date were excluded. New users were followedfrom the start date until the first of the following: end of enrollment
in the database, death, or end of the study period.2.3 | Evaluation of the effectiveness of risk
minimization measures
We compared the prevalence of new users of cilostazol and the fre-
quency of conditions targeted by risk minimization measures included
in the labeling (Table 1) before (2002‐2012) and after (2014) the risk
minimization measures were implemented in 2013 (Figure 1).
Table 1 describes the labeling changes and the conditions evaluated
to assess their impact. These conditions were prevalence of smoking
cessation, frequency of early monitoring of patients taking cilostazol,
frequency of patients with early discontinuation of cilostazol, fre-
quency of cardiovascular conditions that were new contraindications,
frequency of concurrent use of 2 or more antiplatelet agents, increase
in monitoring for users at increased risk of serious cardiac events, and
frequency of concurrent use of high‐dose cilostazol and potent inhib-
itors of CYP3A4 or CYP2C19.12,13 Information on smoking was avail-
able inTHIN, EpiChron, and SIDIAP. In Sweden, we evaluated smoking
using diagnosis codes for smoking‐related disease and use of smoking‐
cessation drugs. Early monitoring of users was assessed by the num-
ber of patients who had at least 1 visit to a specialist (vascular surgery,
cardiology, diabetology) 2 to 4 months after the start date. These visits
were classified as related to peripheral arteriopathy. In Sweden, eval-
uation of visits was restricted to hospitals and hospital outpatient
clinics. In GePaRD, diagnoses are recorded on a quarterly basis, and
visits were evaluated by the number of patients who had at least 1
diagnosis for intermittent claudication recorded in the 3 months fol-
lowing the quarter in which cilostazol was started. Early discontinua-
tion of cilostazol was defined as discontinuation occurring within the
first 3 months of treatment. New cardiovascular contraindications
FIGURE 1 Study timeline in relation to the implementation of risk
minimization measures
CASTELLSAGUE ET AL. 955were unstable angina pectoris and recent myocardial infarction or cor-
onary intervention. We also evaluated the prevalence of contraindica-
tions in the labeling before implementation of labeling changes (ie, old
contraindications): severe renal impairment, moderate to severe
hepatic impairment, congestive heart failure, predisposing factors for
bleeding (active peptic ulcer, hemorrhagic stroke within the prior
6 months, proliferative diabetic retinopathy, and poorly controlled
hypertension), and history of specific arrhythmias. Concurrent use of
cilostazol and 2 or more antiplatelet agents was defined as overlaps
of the intended duration of prescriptions of each medication. Monitor-
ing of patients at increased risk of serious cardiac events was evalu-
ated by comparing rates of visits to general practitioners or
specialists between patients with and without a history of arrhyth-
mias, hypotension, or coronary heart disease during continuous use
of cilostazol. In GePaRD, monitoring was expressed as the number
of diagnoses per patient‐year of continuous use, because only the first
visit to the same physician is recorded during a quarter. Continuous
use of cilostazol was defined as the total number of days covered by
all periods of consecutive prescriptions, allowing for a maximum 60‐
day gap. Concurrent use of high‐dose cilostazol and potent inhibitors
of CYP3A4 or CYP2C19 was defined at the start date and during fol-
low‐up. Concurrent use at the start date was defined as having a pre-
scription for an interacting medication within 3 months before the
start date of high‐dose cilostazol. Concurrent use during follow‐up
was defined as having a prescription for an interacting medication dur-
ing the periods of continuous use of high‐dose cilostazol. In THIN and
EpiChron, daily dose of cilostazol was calculated from strength of
product, package quantity, and dosage instructions. In Sweden, daily
dose was calculated assuming a twice‐daily dosage based on the
results of a manual review of free text associated with dispensings.
In GePaRD, a twice‐daily dosage was also assumed. In SIDIAP,TABLE 1 Cilostazol labeling changes and study variables
Labeling Section Labeling Changes
Indication Second‐line use after lifestyle modifications, inc
smoking cessation and (supervised) exercise p
failed to sufficiently improve symptoms
Physician reassessment of patients after 3 mont
treatment with a view to discontinuing cilosta
an inadequate effect is observed
New contraindications Unstable angina pectoris, myocardial infarction
last 6 months, or a coronary intervention in t
6 months
Concomitant treatment with 2 or more addition
antiplatelet agents (eg, aspirin, clopidogrel)
Old contraindicationsa Severe renal impairment, moderate to severe he
impairment, congestive heart failure, predispo
factors for bleeding (active peptic ulcer, hemo
stroke within the prior 6 months, proliferative
retinopathy, and poorly controlled hypertensi
Warnings and
precautions
Close monitoring of patients at increased risk fo
cardiac adverse events as a result of increase
rate, eg, patients with stable coronary disease
history of tachyarrhythmias
Posology Reduction of the dose to 50 mg twice daily in p
receiving medicines that strongly inhibit CYP3
CYP2C19
aContraindications already included in the labeling of cilostazol before new labevaluation of daily dose was not conducted, as information on dosage
instructions was not available. Medical diagnoses and use of medica-
tions were ascertained through the coding system specific to each
database (Table S1, online supporting information).2.4 | Analysis
The annual prevalence of cilostazol use was calculated in each data-
base as the ratio between the number of cilostazol users (prevalent
and new users) in a specific year and the database population. The
cumulative proportion of patients discontinuing cilostazol was calcu-
lated using survival analysis. Rates of visits were calculated as the
number of visits per 100 person‐years of continuous use of cilostazol,
except in GePaRD, where the number of diagnoses per patient‐year
was used. Crude incidence rate ratios and 95% confidence intervals
(CIs) were estimated to compare rates of visits between patients at
high risk of cardiac events and patients not at high risk.
At RTI‐HS (THIN data), SIDIAP, Sweden, and GePaRD,
analyses were conducted using SAS version 9.3 or 9.4 (Cary, NC:
SAS Institute Inc.). Stata v13.0 (StataCorp, 2013) was used in the
EpiChron cohort. Stata v13.1 and R 3.1 (R CoreTeam, 2013) were also
used in SIDIAP.Study Variable
luding
rograms,
Prevalence of current smoking at the start date
Second‐line use and supervised exercise were not
evaluated
hs of
zol where
Visit to the general practitioner or specialist (cardiologist,
vascular specialist, or diabetologist) between 2 and
4 months after the start date
Visit related to intermittent claudication
Discontinuation within 3 months of treatment
within the
he last
Prevalence of new contraindications before the start date
al Concurrent use at the start date or use of 2 or more
antiplatelet agents during continuous use of cilostazol
patic
sing
rrhagic
diabetic
on)
Prevalence of old contraindications before the start date
r serious
d heart
or a
Rates of visits to general practitioner or specialist during
continuous use of cilostazol in patients at increased
and not increased risk of cardiac adverse events
atients
A4 or
Prevalence of concurrent use of high‐dose cilostazol and
CYP3A4 or CYP2C19 potent inhibitors, and percentage
of concurrent users with reduction of high dose
eling was recommended by the European Medicines Agency.
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tional review board; ethics committees for THIN, EpiChron, IDIAP, and
Sweden; and the statutory health insurance providers and German
Federal Insurance Authority in Germany. The protocol was approved
by the EMA and posted in the EU PAS Register in March 2013 (EU
PAS ID: 3596).14FIGURE 2 Annual prevalence of use of cilostazol before and after
the implementation of risk minimization measures (per 100 000
population). EpiChron, EpiChron cohort from Aragon Health Sciences
Institute (IACS), Aragon, Spain; GePaRD, German
Pharmacoepidemiological Research Database; SIDIAP, Information
System for the Improvement of Research in Primary Care Database,
Catalonia, Spain; THIN, The Health Improvement Network. Prevalence
was not estimated for 2013, the year of implementation of risk
minimization measures3 | RESULTS
3.1 | Prevalence and patterns of use
We included 22 593 and 1821 new users of cilostazol before and after
implementation of risk minimization measures, respectively (Table 2).
EpiChron and SIDIAP contributed the largest number of users in both
periods. The annual prevalence of use of cilostazol decreased after
2011 to 2012 in all study populations (Figure 2). The reduction in
annual prevalence was calculated by comparing the period after imple-
mentation of risk minimization measures to the year with the maxi-
mum prevalence before implementation of risk minimization
measures. The reduction ranged from −16.1% in THIN to −57.1% in
SIDIAP. There was a slightly higher proportion of men than women
in all study populations in both periods (Table 2). After implementation
of risk minimization measures, the median age decreased in men and
women in EpiChron, SIDIAP, and Sweden. The median age in women
also decreased in GePaRD. The proportion of users prescribed a daily
dose of 200 mg decreased after implementation of risk minimization
measures in all study populations except Sweden. Discontinuation of
cilostazol at 3 months and at 6 months after the start of treatmentTABLE 2 Characteristics and patterns of use in new users of cilostazol b
Characteristic THIN UK EpiChron Aragon Spain
Study period
Before 2002‐2012 2009‐2012
After 2014 2014
Number of users
Before 1,528 4,024
After 104 367
Men (%)
Before 65.6 72.2
After 66.3 85.6
Median age before/after (years)
Men 68.0/69.0 69.0/65.9
Women 71.0/74.0 73.9/69.7
Daily dose 200 mg (%)
Before 85.7 77.3
After 31.7 7.1
Discontinuation before/after (%)
<1 month 28.7/38.5 33.9/25.5
<3 months 52.9/64.4 51.9/30.4
<6 months 62.2/70.3 60.5/35.2
<12 months 71.3/70.3 69.1/45.8
The terms before and after refer to the periods before and after the implement
EpiChron, EpiChron cohort from the Aragon Health Sciences Institute (IACS);
available; SIDIAP, Information System for the Improvement of Research in Primincreased after implementation of risk minimization measures inTHIN,
SIDIAP, and Sweden; decreased in EpiChron; and practically did not
change in GePaRD.3.2 | Comorbidity and comedications
The most frequent comorbidities and comedications before and after
implementation of risk minimization measures are presented in Tablesefore and after the implementation of risk minimization measures
SIDIAP Catalonia Spain Sweden GePaRD Germany
2009‐2012 2008‐2012 2007‐2011
2014 2014 2014
10,142 2,887 4,012
771 149 430
77.3 52.3 73.3
78.5 58.4 70.9
68.0/65.0 72.4/69.7 69.0/70.0
75.0/68.0 75.0/72.5 70.0/69.0
NA 78.1 87.9
NA 79.9 77.0
22.2/20.5 38.3/43.0 39.4/40.7
40.6/58.1 39.4/47.9 51.9/52.8
50.4/77.3 65.2/70.6 64.9/68.6
64.6/100.0 81.9/82.6 77.8/77.5
ation of risk minimization measures.
GePaRD, German Pharmacoepidemiological Research Database; NA, not
ary Care; THIN, The Health Improvement Network; UK, United Kingdom.
CASTELLSAGUE ET AL. 957S2 and S3, online supporting information. The patterns of comorbidi-
ties and comedications remained similar before and after implementa-
tion of risk minimization measures. Cardiovascular disease was the
most frequent comorbidity in all study populations in both periods,
followed by diabetes, skin disorders, renal diseases, and bleeding dis-
orders. Antihypertensives, lipid‐modifying agents, platelet aggregation
inhibitors, statins, and proton pump inhibitors were the most frequent
comedications.
Most cilostazol users were treated concurrently with interacting
medications in both periods; however, in EpiChron, SIDIAP, and Swe-
den, concurrent treatment decreased after the risk minimization mea-
sures were implemented. Concurrent use of cilostazol and potent
inhibitors of CYP3A4 or CYP2C19 also decreased in all databases.
The decrease ranged from 2.7% (Sweden) to 22.3% (THIN) before risk
minimization and from 0.7% (Sweden) to 17.3% (THIN) after risk min-
imization (Table S4, online supporting information).3.3 | Evaluation of the effectiveness of risk
minimization measures
Results of the assessment of the risk minimization measures are pre-
sented in Table 3 and Figures 2 and 3. After implementation of risk
minimization measures, the parameters that improved in all study pop-
ulations were the prevalence of new cardiovascular contraindications
and the concurrent use of cilostazol 200 mg per day and interacting
medications, including potent inhibitors of CYP3A4 or CYP2C19. Dis-
continuation of cilostazol within the first 3 months of treatment, con-
current use with 2 or more antiplatelet agents, and monitoring of
patients at high risk of cardiac events improved in at least 3 of the
study populations. The prevalence of current smoking at the start date
decreased only in EpiChron. Overall, Sweden, followed by THIN and
EpiChron, were the study populations with the highest number of
parameters improved after implementation of labeling changes
(Figure 2). We also evaluated the prevalence of old contraindications
(in the labeling before labeling changes) before and after implementa-
tion of risk minimization measures (Table S5, online supporting infor-
mation). After labeling changes, the prevalence of old
contraindications decreased in THIN (10.0% before, 8.7% after) and
EpiChron (6.2%, 5.5%), increased in SIDIAP (39.1%, 51.5%) and
GePaRD (51.8%, 54.7%), and was the same as before labeling changes
in Sweden (12.2%, 12.1%).4 | DISCUSSION
In this study, we evaluated the effectiveness of risk minimization mea-
sures for the use of cilostazol in the UK, Spain, Sweden, and Germany.
The study addressed the concerns raised during the EMA Article 31
cilostazol referral and the requirement to evaluate the risk minimiza-
tion measures through drug utilization studies. The characteristics of
new users of cilostazol remained similar before and after implementa-
tion of risk minimization activities. In both periods, there was a higher
proportion of men than women, and most users were elderly and had
a high prevalence of comorbidity, especially cardiovascular disease,
and concurrent use of other medications. In general, the riskminimization measures were effective in all study populations, as indi-
cated by the marked decrease in the prevalence of cilostazol use, the
decrease of use in the presence of new cardiovascular contraindica-
tions, and the lower concurrent use of cilostazol and interacting med-
ications, including CYP2C19 and CYP3A4 potent inhibitors. Early
monitoring and discontinuation of cilostazol, concurrent use with 2
or more antiplatelet agents, monitoring of users at high risk of cardio-
vascular events, and the prevalence of old contraindications improved
in most study populations after labeling changes. Current smoking at
the initiation of cilostazol improved only in EpiChron, in Spain. The
prevalence of use of cilostazol started diminishing in some countries
while regulatory reviews were ongoing and before actual implementa-
tion of the labeling changes. Prevalence of use continued decreasing
until 2014, after implementation of risk minimization measures. The
decrease is consistent with the reduction of cilostazol sales in the
study countries and Europe overall, according to data provided by
Otsuka, the manufacturer of cilostazol. The characteristics of users
of cilostazol in this study are in line with those from a study conducted
in Spain.15 In that study, most users were elderly and had a high prev-
alence of comorbidity and use of comedications.
A strength of our study is the use of automated health databases,
allowing evaluation of medication use as prescribed in routine health
care without interfering with or modifying clinical practice. The rela-
tion between the labeling changes and the variables used to measure
them is of great relevance to the interpretation of the study. Choice
of measures was challenging given the data available across data
sources. For some labeling changes, there was no information; only
proxies or partial data could be used. Early in the design discussions,
considerable time was devoted to this aspect, and whether de novo
data collection via prescriber questionnaires would be more informa-
tive. In the end, given the challenges of the latter approach, including
potential self‐selection bias of participating health care practitioners,
we selected the database approach as the best means to evaluate
the impact of the labeling changes overall. This permitted us to evalu-
ate the effectiveness of the cilostazol risk minimization measures in
different countries and health systems.
Several considerations should be considered when reviewing our
results. As mentioned previously, information for some labeling
changes (eg, physician reassessment of treatment) was not available
in the study databases. The use of proxies for these items could lead
to some misclassification of the actual labeling change before and
after implementation of risk minimization measures. Also, as in any
before‐after study without a comparator mediation, factors other than
the risk minimization measures could have influenced the changes
observed in the conditions included in the new labeling of cilostazol.
The EMA cilostazol referral itself could affect the prescribing of
cilostazol, as physicians' and prescribers' awareness of the potential
safety issues may have increased during the referral period, before
the risk minimization measures were implemented. In fact, the
decreasing prevalence of cilostazol use beginning in 2011 to 2012,
before implementation of risk minimization measures in some data-
bases, is consistent with an effect of the referral process itself.
The period before implementation of risk minimization measures
included many users in most study populations as the study periods
covered several years: approximately 3.5 years in EpiChron and
TABLE 3 Assessment of labeling changes before and after the implementation of risk minimization measures
Labeling Change THIN UK EpiChron Aragon Spain SIDIAP Catalonia Spain Sweden GePaRD Germany
Indication
Second‐line use after lifestyle modifications, including smoking cessation
Smoking (%)a
Before 30.4 15.9 32.3 3.2 NA
After 37.5 8.2 45.5 4.0 NA
Physician reassessment of patients after 3 months of treatment with a view to discontinuing cilostazol where an inadequate effect is observed
Early monitoring (%)b
Before 49.6 21.3 53.5 8.5 62.2
After 69.2 24.2 10.8 13.0 63.0
Early discontinuation (%)c
Before 52.9 51.9 40.6 39.4 50.3
After 64.4 30.4 58.1 47.9 52.8
New contraindications
New cardiovascular contraindications (%)d
Before 1.5 1.7 3.0 5.2 11.6
After 1.0 0.3 0.9 2.7 10.7
Concurrent treatment with ≥2 antiplatelet agents (%)
Before 9.8 13.5 6.3 8.4 7.5
After 2.9 7.4 6.7 6.7 7.7
Warnings and precautions
Monitoring of patients at high risk of cardiac events (RR, 95% CI)e
Before 1.08 (1.05‐1.10) 1.12 (1.10‐1.13) 1.19 (1.17‐1.22) 1.90 (1.84‐1.97) 1.03 (0.99‐1.08)
After 0.88 (0.71‐1.09) 0.97 (0.90‐1.05) 1.75 (1.63‐1.88) 2.08 (1.65‐2.64) 1.24 (0.99‐1.56)
Posology
Concurrent use of cilostazol 200 mg and interacting medications (%)
Before 78.7 76.9 NA 67.5 69.4
After 27.9 3.6 NA 63.8 61.6
Concurrent use of cilostazol 200 mg and potent CYP3A4 or CYP2C19 inhibitors (%)f
Before 19.6 10.0 NA 2.1 3.6
After 5.8 0.0 NA 0.7 1.9
The terms before and after refer to the periods before and after the implementation of risk minimization periods.
CI, confidence interval; EpiChron, EpiChron cohort from Aragon Health Sciences Institute (IACS); GePaRD, German Pharmacoepidemiological Research
Database; NA, not available; RR, rate ratio; SIDIAP, Information System for the Improvement of Research in Primary Care; THIN, The Health Improvement
Network; UK, United Kingdom.
aCurrent smoking at the start date. In Sweden, smoking was evaluated only through smoking‐related diagnoses and dispensations for smoking‐cessation
drugs.
bPercentage of users with at least 1 visit to a specialist (vascular surgery, cardiology, diabetology) 2 to 4 months after the start date.
cDiscontinuation of cilostazol within the first 3 months of treatment.
dUnstable angina pectoris and myocardial infarction or coronary intervention within the last 6 months.
eRate ratio of visits to the general practitioner or specialist between users with and without increased risk of serious cardiac events (arrhythmias, hypoten-
sion, or coronary heart disease). In GePaRD, visits were expressed as the number of diagnoses per patient‐year of continuous use, because only the first
visit to the same physician is recorded during a quarter.
fPotent CYP3A4 or CYP2C19 inhibitors: lansoprazole, fluvoxamine, nefazodone, ticlopidine, clarithromycin, troleandomycin, indinavir, ritonavir, nelfinavir,
mibefradil, ketoconazole, and itraconazole.
958 CASTELLSAGUE ET AL.SIDIAP and 10 years in THIN. However, the period after the risk min-
imization measures was restricted to new users identified during
2014. Therefore, the “after” period included only a small number of
users in all databases, with a shorter time of follow‐up, increasing ran-
dom variability and potential underascertainment of variables mea-
sured during cilostazol use in the follow‐up period. Also, restricting
the period after implementation of risk‐minimization measures to
1 year did not allow assessment of the long‐term effectiveness of
these measures. Long‐term low compliance of lifestylerecommendations among patients with peripheral arterial disease has
been reported.16 Evaluation of cilostazol users before implementation
of risk minimization measures reflects the average profile of users
through a long period and not the actual profile immediately before
risk minimization activities were implemented. Characteristics of users
and patterns of use could have changed since cilostazol became avail-
able for the treatment of intermittent claudication; patients and health
care practitioners in 2012 may have been more aware of potential
problems than those initiating cilostazol in 2002. However, we believe
FIGURE 3 Summary of improvement in or worsening of
characteristics impacted by risk minimization measures, by data
source. GePaRD, German Pharmacoepidemiological Research
Database; NA, not available; SIDIAP, Information System for the
Improvement of Research in Primary Care Database; THIN, The
Health Improvement Network; UK, United Kingdom. Classification
was based on a 5% change from before to after the implementation of
risk minimization measures. Values below 5% were considered to
represent no change. + = improvement after the labeling changes;
− = worsening after the labeling changes; equal = no changes after the
labeling changes
CASTELLSAGUE ET AL. 959the concern is not great because it does not impact the Spanish data
sources, which provided the largest number of users. In the United
Kingdom, a small monotonic increase in the prevalence of users during
the research period was observed from 2003 to 2011, and use of
cilostazol increased in Germany from 2007 to 2011. Neither situation
suggests a strong awareness of potential problems with cilostazol. In
Sweden, a small decrease in the prevalence of use of cilostazol
occurred in the last 3 years; however, we have data for only 4 years,
and the prevalence of users of cilostazol in 2012 (13 per 100 000) is
equivalent to that in 2009 (13 per 100 000) and not very different
from the maximum prevalence (16.5 per 100 000 in 2010), limiting
our concern about lack of comparability.
Changes in the recording of diagnoses in the study databases
before and after the risk minimization measures could affect the com-
parison of results between the 2 periods. For example, after labeling
changes, the recording of the ankle‐brachial index was implemented
in SIDIAP, resulting in a higher prevalence of diagnoses. In addition,
clinical guidelines and the introduction of new and generic medica-
tions in the period after labeling changes also need to be considered.For example, direct oral anticoagulants were introduced recently in
most countries; health services in Catalonia (SIDIAP) tried to reduce
the consumption of proton pump inhibitors and encouraged general
practitioners to review patient prescriptions periodically, and atorva-
statin became generic in Germany.
Differences in the type of databases included in this study could
introduce variability in the baseline prevalence of conditions across
the study populations before and after implementation of risk minimi-
zation measures. Thus, information recorded in THIN, EpiChron, and
SIDIAP was based on primary care electronic medical records, infor-
mation recorded in Sweden on inpatient and outpatient hospital dis-
charge diagnoses, and information recorded in GePaRD on insurance
claims from ambulatory care and hospital admissions. This impacted
the evaluation of some variables such as smoking status at the start
date, which in Sweden was ascertained indirectly using diagnosis
codes related to smoking‐related illnesses, and the prevalence was
underestimated. History of smoking‐related diagnoses could be a poor
marker of current smoking, leading to misclassification. Although dif-
ferences between databases limited some baseline comparisons,
within‐database comparisons, before and after risk minimization, pro-
vided an efficient framework to evaluate the impact of risk minimiza-
tion measures in different countries and health systems.
Results from this study can be generalized to each respective
country. The THIN database includes information for approximately
6% of the UK population, and the population covered in the database
has been shown to have demographics, deprivation index, disease
prevalence, and mortality rates similar to the overall UK population.3
In Spain, EpiChron covers all the primary care practices of the public
health system in the region of Aragon, and SIDIAP covers about
80% of those in the region of Catalonia.17,18 In Sweden, data included
in the study involve the entire population. In Germany, the data cov-
ered approximately 10% of the German population, about 8.4 million
and 8.0 million insured members before and after implementation of
risk minimization measures, respectively.
Overall, results from this study conducted in the United Kingdom,
Spain, Sweden, and Germany are compatible with a positive effect of
implementing risk minimization measures in all the study populations,
as indicated by the lower prevalence of cilostazol use and the
improvement of most utilization parameters evaluated. However, the
risk minimization measures impacted the prevalence of smoking at
the time of initiating cilostazol treatment in only 1 of the 4 study pop-
ulations where smoking was evaluated. These findings should be
interpreted with caution given the random variation introduced by
the small number of new users of cilostazol and the short time of fol-
low‐up after implementation of risk minimization measures.ACKNOWLEDGEMENTS
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